Posted by Admin | 11:40 AM

It only took until 2013, but the US Food and Drug Administration finally secured guilty pleas and fines.  The basics are in an Associated Pr...

Labels: adulterated drugs, adverse effects, crime, Daiichi Sankyo, FDA, manufacturing problems, outsourcing, Ranbaxy

Posted by Admin | 8:31 AM

This is becoming a familiar narrative on Health Care Renewal : top health care leaders continue to enrich themselves while their organizati...

Labels: adverse effects, Amgen, executive compensation, kickbacks, legal settlements

Posted by Admin | 10:30 AM

Some reporting by Bloomberg provides more evidence about what happens when direct care of the most vulnerable patients is commercialized.  T...

Labels: adverse effects, Bain Capital, CRC Health, narcotics, private equity

Posted by Admin | 8:52 AM

At least here in these United States, our health care corporatism is bipartisan.  Here we present a sorry story of how a company that should...

Labels: adverse effects, Amgen, corporatism, crime, deception, kickbacks, revolving doors, stealth health policy advocacy

Posted by Admin | 1:50 PM

Now it's Amgen's turn to settle and plead.  Per the New York Times, The biotechnology giant Amgen marketed its anemia drug Aranesp ...

Labels: adverse effects, Amgen, corporate integrity agreements, crime, impunity, legal settlements

Posted by Admin | 11:45 AM

Suppression of data about defects in and failures of implantable cardiac defibrillators (ICDs) was one of the big issues we featured in the ...

Labels: adverse effects, defective devices, ICD, medical devices, secrecy, St Jude Medical, suppression of medical research

Posted by Admin | 10:56 AM

In the US, we have been engaged in an experiment involving handing over an ever increasing proportion of direct patient care to for-profit c...

Labels: adverse effects, boards of trustees, conflicts of interest, fraud, Harden Healthcare, hospices

Posted by Admin | 5:00 AM

A striking illustration of the hazards to patients' and the public's health from health care organizational leaders using fashionabl...

Labels: adulterated drugs, adverse effects, China, heparin, manufacturing problems, outsourcing